Literature DB >> 2846828

Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography.

B J Morris1, M J Millan, A Herz.   

Abstract

The neurochemical basis for the supersensitivity to mu or kappa opiate agonists observed after chronic naloxone infusion (reported in the preceding paper) has been investigated using the technique of quantitative in vitro autoradiography. The binding of [3H]-D-Ala2MePhe4Glyol enkephalin (3H-DAGO) to mu opioid sites was increased in many brain regions after chronic administration (7 days) of a low dose of naloxone (0.5 mg/kg/hr). The greatest increases were seen in the hippocampal strata moleculare and lucidum. The binding of [3H]-D-Ala2-D-Leu5 enkephalin (3H-DADL) to delta sites and of [3H]-bremazocine to kappa sites were not significantly affected in any region. In contrast, after administration of a higher dose of naloxone (3.0 mg/kg/hr), the binding to mu, delta and kappa sites was increased in many brain areas, suggesting that up-regulation is observed only when a sufficient proportion of the receptors in vivo are occupied by the antagonist. However, a different regional pattern of up-regulation was seen for each class of opiate binding site. The greatest increases in kappa binding in the brain were seen in the periaqueductal gray and the hippocampal molecular and pyramidal cell layers. The substantia nigra showed up-regulation of kappa but not of mu sites. Differences in the pattern of mu and kappa binding site up-regulation were also noted in the spinal cord. This regionally specific modulation of opiate binding sites suggests that, for each receptor type, the level of tonic activation varies between individual brain areas. In addition, the data demonstrate that all three types of opiate receptor can undergo up-regulation "in vivo."

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846828

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.

Authors:  R A de Ligt; A P Kourounakis; A P IJzerman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice.

Authors:  Alexis Bailey; Rachel M Hawkins; Susanna M O Hourani; Ian Kitchen
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

3.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

4.  Involvement of mu-opioid receptors in the antitussive effects of pentazocine.

Authors:  J Kamei; K Katsuma; Y Kasuya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

5.  Increased sensitivity to rate-altering and discriminative stimulus effects of morphine following continuous exposure to naltrexone.

Authors:  A M Young; S R Mattox; M D Doty
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.

Authors:  B J Morris; M J Millan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

7.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

8.  A genetic determinant of the striatal dopamine response to alcohol in men.

Authors:  V A Ramchandani; J Umhau; F J Pavon; V Ruiz-Velasco; W Margas; H Sun; R Damadzic; R Eskay; M Schoor; A Thorsell; M L Schwandt; W H Sommer; D T George; L H Parsons; P Herscovitch; D Hommer; M Heilig
Journal:  Mol Psychiatry       Date:  2010-05-18       Impact factor: 15.992

9.  The effect of chronic treatment with naltrindole, a selective delta-opioid antagonist, on mu-opioid receptor-mediated antinociception in diabetic mice.

Authors:  J Kamei; N Kawashima; Y Iwamoto; T Suzuki; H Nagase; M Misawa; Y Kasuya
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists.

Authors:  C A Paronis; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.